Work carried out in the Australian Northern Territories, has led to the development of a possible S. pyogenes “30mer” vaccine which is composed of 30 pharyngitis-associated type-specific antigens from the S. pyogenes M protein. Here, MYOM2 is linked to pharyngitis.